Fin Trust Capital Advisors, LLC Eagle Pharmaceuticals, Inc. Transaction History

Fin Trust Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$44.58 - $52.6 $7,355 - $8,679	-165 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $549 - $682	-12 Reduced 6.78%	165 $8,000
Q3 2020 Nov 10, 2020	BUY	$37.02 - $51.28 $5,182 - $7,179	140 Added 378.38%	177 $8,000
Q2 2020 Sep 11, 2020	BUY	$43.24 - $55.02 $1,599 - $2,035	37 New	37 $2,000
Q2 2020 Aug 14, 2020	SELL	$43.24 - $55.02 $3,848 - $4,896	-89 Closed	0 $0
Q3 2019 Oct 29, 2019	BUY	$53.25 - $59.98 $372 - $419	7 Added 8.54%	89 $5,000
Q1 2019 May 09, 2019	SELL	$38.66 - $51.82 $14,265 - $19,121	-369 Reduced 81.82%	82 $4,000
Q4 2018 Feb 11, 2019	BUY	$36.72 - $67.73 $16,560 - $30,546	451 New	451 $18,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.